A trial to study the association of high circulating neuregulin-1 with clinical benefit in EGFR wild-type non small cell lung cancer patients treated with rilotumumab and erlotinib

Trial Profile

A trial to study the association of high circulating neuregulin-1 with clinical benefit in EGFR wild-type non small cell lung cancer patients treated with rilotumumab and erlotinib

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Aug 2016

At a glance

  • Drugs Erlotinib (Primary) ; Rilotumumab (Primary)
  • Indications Non-small cell lung cancer
  • Focus Pharmacodynamics
  • Most Recent Events

    • 04 Aug 2016 New trial record
    • 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top